3-(4-dimethylamino-naphthalen-1-ylmethylene)-1-3-dihydro-indol-2-one and lysophosphatidic-acid

Lysophosphatidic acid (LPA) is a low-molecular-weight lipid growth factor, which binds to G-protein-coupled receptors. Previous studies have shown that LPA enhances vascular endothelial growth factor-A (VEGF-A) expression in cancer cells and promotes angiogenesis process. However, the roles of LPA in lymphatic vessel formation and lymphangiogenesis have not been investigated. Here, we demonstrated that LPA up-regulated VEGF-C mRNA and protein expressions in human umbilical vein endothelial cells (HUVECs). Furthermore, the expression levels of lymphatic markers, including Prox-1, LYVE-1 and podoplanin, were enhanced in LPA-stimulated tube forming endothelial cells in vitro and in vivo. Moreover, we showed that pretreatment with MAZ51, a VEGFR-3 kinase inhibitor, and introduction of VEGFR-3 siRNA suppressed LPA-induced HUVEC tube formation and lymphatic marker expressions. These results demonstrated that LPA enhances expression of lymphatic markers through activating VEGF-C receptors in endothelial cells. This study provides basic information that LPA might be a target for therapeutics against lymphangiogenesis and tumor metastasis.

Topics: Biomarkers; Cell Proliferation; Cells, Cultured; Endothelial Cells; Homeodomain Proteins; Humans; Indoles; Lymphocytes; Lysophospholipids; Membrane Glycoproteins; Naphthalenes; RNA, Messenger; Tumor Suppressor Proteins; Up-Regulation; Vascular Endothelial Growth Factor C; Vesicular Transport Proteins